GATA3 polyclonal antibody
- Known as:
- GATA3 pab (anti-)
- Catalog number:
- PAB18658
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- GATA3 polyclonal antibody
Related genes to: GATA3 polyclonal antibody
- Gene:
- GATA3 NIH gene
- Name:
- GATA binding protein 3
- Previous symbol:
- -
- Synonyms:
- HDR
- Chromosome:
- 10p14
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-03
- Date modifiied:
- 2016-10-05
Related products to: GATA3 polyclonal antibody
Related articles to: GATA3 polyclonal antibody
- Late-Onset Preeclampsia (LoPE) results in T regulatory cell (Treg) disturbance in the maternal compartment but its effect on the fetal Treg population is not completely understood. The study investigates the fetal aspect of LoPE by analysing cord blood and gene expression profiles of Treg-related (FOXP3, CTLA4, GATA3) and angiogenesis-related genes (VEGF, MMP2, MMP9), alongside assessing the blood gas parameters of the foetus. - Source: PubMed
Publication date: 2026/09/21
Yellanki Yashwanth ChowdaryReddy Rachamalla ChandramouliPatil Mallanagouda MPatil NeelammaSrungavarapu RevathiHatterkihal Ifat FatimaKadakol Gurushantappa - Patent ductus arteriosus (PDA) is a common congenital heart disease (CHD) with a complex genetic basis. The transcription factor MEF2C plays a critical role in cardiac development, but the role of promoter region variants in PDA has not been explored. This study aimed to identify MEF2C promoter variants in PDA patients and investigate their functional consequences. We sequenced the MEF2C promoter region in 318 children with PDA and 306 healthy controls. Identified variants were subjected to dual-luciferase reporter assays in A7r5 vascular smooth muscle cells to assess transcriptional activity. Bioinformatics (JASPAR) and electrophoretic mobility shift assays (EMSA) were used to predict and validate changes in transcription factor binding. Seventeen variants were identified, of which seven were present exclusively in PDA patients. Three variants were novel. Dual-luciferase assays showed that six variants significantly altered promoter activity compared to wild-type (range 69.6%-82.3%). JASPAR prediction revealed that these variants affected binding sites for 16 transcription factors, including GATA1, GATA2, GATA3, STAT3, ZEB1 and E2F1. EMSA confirmed altered DNA-protein binding patterns for all six variants, and super-shift assays further validated that the g.24571 A > G variant specifically disrupts GATA3 binding. This is the first study to identify functionally relevant MEF2C promoter variants in PDA. Our findings suggest that dysregulation of MEF2C through promoter variants may contribute to PDA pathogenesis by disrupting critical transcription factor interactions. These results extend the genetic landscape of PDA beyond coding regions and provide new insights into the molecular mechanisms of CHD. - Source: PubMed
Wang Shao-JieChen Huan-XinYang QinHe Guo-Wei - Current breast cancer biomarkers rely predominantly on protein-coding transcriptomes, leaving the regulatory information encoded by enhancer RNAs (eRNAs) largely unexploited. Here, we profiled eRNA expression across 1073 The Cancer Genome Atlas Breast Cancer (TCGA-BRCA) samples integrated with The Cancer eRNA Atlas annotations, using GTEx healthy breast tissue ( = 179) as a curated normal reference. For prognostic stratification, least absolute shrinkage and selection operator (LASSO)-Cox regression identified a 10-eRNA signature that stratified patients into high- and low-risk groups in both training ( <.0001) and independent testing cohorts ( = 0.0022), with a 3-year time-dependent area under the curve (AUC) of 0.743. Multivariate Cox analysis confirmed the signature as an independent predictor [hazard ratio = 3.176, 95% confidence interval (CI): 2.075-4.864, <.001]. Multi-omics network integration linked these prognostic eRNAs to regulatory hubs centered on the /// axis. For early-stage detection, we developed a 19-eRNA panel via bootstrap LASSO feature selection and benchmarked ten classifiers; a Multilayer Perceptron achieved the best generalization (AUC = 0.959, 95% CI: 0.925-0.986) on an independent cohort (GSE225846). Both modules were deployed in eRNACare, a publicly accessible web application for individualized survival and tumor probability scoring. These findings establish eRNAs as a complementary noncoding layer to conventional messenger RNA classifiers, with clinical potential for breast cancer risk stratification, therapeutic guidance, and early detection. - Source: PubMed
Publication date: 2026/09/25
Xia JunhuanTian JingwenCao YutingZhang SuhanQian WeiyeQi YananHuang Hao - Congenital heart defects (CHDs) are defects present at birth that can often lead to perinatal death, or, rarely, can be asymptomatic and detected later in life. Ectopia cordis is a rare type of malformation in which the heart is not located in its normal position. Other congenital abnormalities can be associated with this condition. In this article, we describe a case of ectopia cordis thoracalis with atrial septal defect in association with unilateral renal agenesis in a male Romanian Spotted calf. Clinical examination, dissection, and whole-genome sequencing were performed to describe and identify a possible cause of the abnormalities. Clinical examination revealed the presence of the heart in the thoracic region, subcutaneously, without apparent impairment of major physiological functions. Upon dissection, the external appearance of the heart was normal. However, the internal examination revealed an atrial septal defect measuring 1 cm in diameter in the proximal third of the interatrial septum. The case presented unilateral agenesis of the left kidney. VEP annotation of the joint callset identified 2270 missense variant annotations predicted as deleterious by SIFT and, separately, 12 high-impact start-loss variants by VEP consequence annotation. The and variants were homozygous in the calf. Analyzing genes involved in cardiac and renal development, the following genes-, , , , , , and had mutations with moderate impact. Mutations in the gene occurred in homozygous states for both the calf and mother genomes, while the gene had two mutations in a homozygous state just in the calf genome, and in a heterozygous state in the mother's genome. One limitation of the present study is the unavailability of the paternal genome for comparative analysis; in addition, maternal genomic profiling did not reveal a contribution to the identified variants. Although the specific pathogenic relevance of the variants detected to the observed phenotype cannot be conclusively established, the findings expand the current genomic knowledge of this rare disorder and provide valuable data for future investigations into its genetic basis. - Source: PubMed
Publication date: 2026/09/14
Herman ViorelMarc SimonaBoldura Oana MariaCărunta AlinaTămaș Anca-AlexandraCrăciun Ioan ClaudiuOlariu-Jurca AdrianOtavă GabrielBadea CorinaMizeranschi Alexandru Eugeniu - Muscle-invasive bladder urothelial carcinoma (MIBUC) is a heterogeneous disease, presenting variable clinical outcomes and therapeutic responses. Although molecular classification provides important prognostic information, its clinical use is limited by cost and technical complexity, making immunohistochemistry (IHC) a practical and reliable surrogate approach. We aimed to investigate the association between IHC-based molecular subtypes and overall survival (OS). We conducted a retrospective study including 75 newly diagnosed MIBUCs over a 4-year period. Tumours were stratified into seven molecular subtypes (LumP, LumNS, LumU, Ba/Sq, NE-like, stroma-rich, and double-positive) using a five-antibody IHC panel (GATA3, CK5/6, p16, FGFR3, and EpCAM). Marker expression was evaluated based on staining intensity and the proportion of positive tumour cells, using predefined, marker-specific cut-off values. OS was assessed for each subtype and compared across groups. Median OS ranged from 5 months (NE-like) to 26 months (stroma-rich and double-positive). LumU demonstrated the highest 1-year survival rate, while the double-positive subtype exhibited the most favourable long-term outcomes, at 2 and 5 years. Conversely, NE-like had the lowest 1-year survival rate, whereas the stroma-rich subtype demonstrated the lowest 2- and 5-year survival rates. No statistically significant difference in OS was identified across molecular subtypes ( = 0.714). Patients ≤65 years experienced significantly longer OS than older patients ( = 0.024). OS was comparable between sexes ( = 0.626) and did not differ significantly according to tumour morphology ( = 0.884). IHC-based molecular classification represents a feasible approach to characterize molecular heterogeneity in MIBUC, with further studies needed to clarify its prognostic significance. - Source: PubMed
Publication date: 2026/09/11
Tătar Andrada-ClaudiaVoidăzan SeptimiuRaicea AndradaPopelea Maria-CătălinaLoghin AndradaBorda Angela